BIO survey warns tariffs would impede biomedical innovation

Tariffs proposed by President Donald Trump on imports from the EU, China, and Canada threaten to “impede access to cures and stifle innovation,” BIO President and CEO John Crowley warned Wednesday.

Crowley cited a survey conducted by BIO that spotlights its members’ concerns about tariffs, including increased costs, as well as R&D and regulatory delays. Tariffs, he said, could have “far reaching and potentially damaging impacts” on the biotech industry, biomedical research and patients...